Kronos Bio (NASDAQ:KRON) Trading 1.1% Higher

Kronos Bio, Inc. (NASDAQ:KRON) shares shot up 1.1% during trading on Wednesday . The company traded as high as $1.00 and last traded at $0.96. 883,997 shares traded hands during trading, an increase of 192% from the average session volume of 302,912 shares. The stock had previously closed at $0.95.

Kronos Bio Trading Up 1.1 %

The business has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $1.12. The stock has a market capitalization of $57.70 million, a P/E ratio of -0.49 and a beta of 1.82.

Kronos Bio (NASDAQ:KRON) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.08. Kronos Bio had a negative return on equity of 58.79% and a negative net margin of 1,791.87%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $1.50 million. As a group, research analysts forecast that Kronos Bio, Inc. will post -1.74 earnings per share for the current year.

Institutional Trading of Kronos Bio

Several institutional investors and hedge funds have recently bought and sold shares of KRON. Cerity Partners LLC purchased a new position in shares of Kronos Bio during the fourth quarter valued at approximately $513,000. Acuta Capital Partners LLC lifted its holdings in shares of Kronos Bio by 128.2% during the third quarter. Acuta Capital Partners LLC now owns 718,739 shares of the company’s stock valued at $934,000 after purchasing an additional 403,739 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Kronos Bio by 6.4% during the third quarter. Acadian Asset Management LLC now owns 614,945 shares of the company’s stock valued at $798,000 after purchasing an additional 36,909 shares during the last quarter. 64.09% of the stock is currently owned by hedge funds and other institutional investors.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.